Literature DB >> 22859271

Functional invadopodia formation through stabilization of the PDPN transcript by IMP-3 and cancer-stromal crosstalk for PDPN expression.

Young Sun Hwang1, Zhang Xianglan, Kwang-Kyun Park, Won-Yoon Chung.   

Abstract

We previously reported that insulin-like growth factor-II mRNA-binding protein-3 (IMP-3) depletion (IMP-3(Δ)) was shown to inhibit invadopodia formation and extracellular matrix degradation capacity in oral squamous cell carcinoma (OSCC) cells. In this study, we found that IMP-3(Δ) cells significantly downregulated the podoplanin (PDPN) level, which resulted in a loss of extracellular matrix degradation activity, although invadopodia was still thriving. From RNA in situ hybridization using a digoxigenin-labeled 3'UTR recognition probe of PDPN and reporter assay with 3'UTR of the PDPN gene cloned downstream from the luciferase reporter gene, we revealed that IMP-3 depletion was shown to be downregulated, which most probably lowered PDPN gene expression by reducing mRNA stabilization. In a xenograft model, PDPN depletion was the cause of a decrease in tumor volume and regional infiltration into nearby stroma. Taken together, transforming growth factor beta 1 increased PDPN expression, which potentiated cancer invasion through increased invadopodia formation and extracellular matrix degradation in the low invasive OSCC cell line. Reciprocally, interleukin-1 beta secreted by OSCC cells, stimulated transforming growth factor beta 1 secretion from stromal fibroblasts to induce PDPN expression in OSCC cells. In addition, a retrospective investigation of OSCC patients found that IMP-3 and PDPN expression significantly correlated with lymph node metastasis of OSCC patients. Moreover, co-expression of IMP-3 and PDPN were frequently detected both in primary and lymph nodes metastatic OSCC cells using immunohistochemical dual staining. Thus, the IMP-3-PDPN axis may be a sensitive target molecule in anti-invadopodia therapy for the treatment of metastatic cancers.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22859271     DOI: 10.1093/carcin/bgs258

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  19 in total

Review 1.  Control of cell migration through mRNA localization and local translation.

Authors:  Guoning Liao; Lisa Mingle; Livingston Van De Water; Gang Liu
Journal:  Wiley Interdiscip Rev RNA       Date:  2014-09-28       Impact factor: 9.957

2.  EGF enhances low-invasive cancer cell invasion by promoting IMP-3 expression.

Authors:  Xianglan Zhang; Im-Hee Jung; Young Sun Hwang
Journal:  Tumour Biol       Date:  2015-09-19

3.  Oncofetal protein IGF2BP3 facilitates the activity of proto-oncogene protein eIF4E through the destabilization of EIF4E-BP2 mRNA.

Authors:  R Mizutani; N Imamachi; Y Suzuki; H Yoshida; N Tochigi; T Oonishi; Y Suzuki; N Akimitsu
Journal:  Oncogene       Date:  2015-11-02       Impact factor: 9.867

4.  IMP3 Predicts Invasion and Prognosis in Human Lung Adenocarcinoma.

Authors:  Jinhai Yan; Qingzhu Wei; Wenjing Jian; Bo Qiu; Jing Wen; Jianghuan Liu; Bo Fu; Xinhua Zhou; Tong Zhao
Journal:  Lung       Date:  2015-11-25       Impact factor: 2.584

5.  Concordant podoplanin expression in cancer-associated fibroblasts and tumor cells is an adverse prognostic factor in esophageal squamous cell carcinoma.

Authors:  Wen-Yu Chuang; Chi-Ju Yeh; Yin-Kai Chao; Yun-Hen Liu; Yu-Sun Chang; Chen-Kan Tseng; Hsien-Kun Chang; Yung-Liang Wan; Chuen Hsueh
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

6.  Constitutive and Inducible Expression of Invasion-related Factors in PC-3 Prostate Cancer Cells.

Authors:  Young Sun Hwang; Paul F Lindholm
Journal:  J Cancer Prev       Date:  2015-06

7.  Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms.

Authors:  Jhon A Ochoa-Alvarez; Harini Krishnan; John G Pastorino; Evan Nevel; David Kephart; Joseph J Lee; Edward P Retzbach; Yongquan Shen; Mahnaz Fatahzadeh; Soly Baredes; Evelyne Kalyoussef; Masaru Honma; Martin E Adelson; Mika K Kaneko; Yukinari Kato; Mary Ann Young; Lisa Deluca-Rapone; Alan J Shienbaum; Kingsley Yin; Lasse D Jensen; Gary S Goldberg
Journal:  Oncotarget       Date:  2015-04-20

8.  Podoplanin is a component of extracellular vesicles that reprograms cell-derived exosomal proteins and modulates lymphatic vessel formation.

Authors:  Patricia Carrasco-Ramírez; David W Greening; Germán Andrés; Shashi K Gopal; Ester Martín-Villar; Jaime Renart; Richard J Simpson; Miguel Quintanilla
Journal:  Oncotarget       Date:  2016-03-29

Review 9.  RNA Binding Protein as an Emerging Therapeutic Target for Cancer Prevention and Treatment.

Authors:  Suntaek Hong
Journal:  J Cancer Prev       Date:  2017-12-30

10.  Podoplanin mediates ECM degradation by squamous carcinoma cells through control of invadopodia stability.

Authors:  E Martín-Villar; B Borda-d'Agua; P Carrasco-Ramirez; J Renart; M Parsons; M Quintanilla; G E Jones
Journal:  Oncogene       Date:  2014-12-08       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.